18F-LW223:一种不受rs6971多态性影响的TSPO示踪剂可定量心肌梗死后巨噬细胞驱动炎症
本研究筛选了新型氟化TSPO示踪剂,发现18F-LW223在体外结合不受rs6971基因多态性影响;在大鼠心肌梗死模型中,18F-LW223 PET/CT可准确检测梗死区巨噬细胞驱动的炎症,结合参数BPTC显著高于正常心肌。
要点
- 18F-LW223与人脑和心脏组织TSPO结合不受rs6971多态性影响。
- 大鼠心肌梗死后7天,梗死区前壁BPTC显著高于正常前壁(32.7±5.0 vs 10.0±2.4 cm3/mL/min,P≤0.001)。
- 18F-LW223具有适合临床转化的体内特性,包括缓慢代谢、高血浆游离分数和适宜剂量学。
核心结论
- 18F-LW223在体外不受rs6971遗传多态性影响,具有良好体内特性,能准确描绘心肌梗死后巨噬细胞驱动的炎症。
研究设计与样本
- 体外竞争结合实验使用51份人脑和29份人心脏组织样本筛选rs6971多态性。
- 采用 naïve 大鼠和小鼠进行体内PET动力学、放射性代谢物和剂量学实验。
- 大鼠行永久性冠状动脉结扎,心肌梗死后7天使用PET/CT扫描,并采用侵入性输入函数。
主要发现
- LW223与人脑和心脏组织TSPO结合不受rs6971多态性影响。
- 在啮齿类动物中,18F-LW223显示与TSPO表达一致的特异性摄取,血液中代谢缓慢(120分钟时母体占69%),血浆游离分数高(38.5%),有效剂量为20.5-24.5 μSv/MBq。
- 心肌梗死组梗死区前壁BPTC显著高于 naïve 动物前壁(32.7 ± 5.0 vs. 10.0 ± 2.4 cm3/mL/min,P ≤ 0.001)。
- 离体免疫荧光染色TSPO和CD68(巨噬细胞标记)与体内BPTC分析显示相同模式。
关键数值与推荐
- 以K1(动脉血浆到组织的转移速率常数)作为灌注替代标志物,校正因示踪剂从血浆到组织转移受损对结合潜力的影响,得到BPTC。
- BPTC在心肌梗死组梗死区前壁为32.7 ± 5.0 cm3/mL/min,显著高于 naïve 动物前壁的10.0 ± 2.4 cm3/mL/min(P ≤ 0.001)。
- 18F-LW223有效剂量为20.5-24.5 μSv/MBq,血浆游离分数为38.5%,120分钟时血液中母体化合物占69%。
临床怎么用
- 18F-LW223有望作为TSPO PET示踪剂用于心肌梗死后炎症的临床评估,且无需考虑rs6971基因型。
- 采用K1校正的BPTC可提高梗死区示踪剂结合定量的准确性,反映巨噬细胞驱动的炎症。
局限性
- 研究主要基于体外结合实验和动物模型,临床转化仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myocardial infarction (MI) is one of the leading causes of death worldwide, and inflammation is central to tissue response and patient outcomes. The 18-kDa translocator protein (TSPO) has been used in PET as an inflammatory biomarker. The aims of this study were to screen novel, fluorinated, TSPO radiotracers for susceptibility to the rs6971 genetic polymorphism using in vitro competition binding assays in human brain and heart; assess whether the in vivo characteristics of our lead radiotracer, 18F-LW223, are suitable for clinical translation; and validate whether 18F-LW223 can detect macrophage-driven inflammation in a rat MI model. Methods: Fifty-one human brain and 29 human heart tissue samples were screened for the rs6971 polymorphism. Competition binding assays were conducted with 3H-PK11195 and the following ligands: PK11195, PBR28, and our novel compounds (AB5186 and LW223). Naïve rats and mice were used for in vivo PET kinetic studies, radiometabolite studies, and dosimetry experiments. Rats underwent permanent coronary artery ligation and were scanned using PET/CT with an invasive input function at 7 d after MI. For quantification of PET signal in the hypoperfused myocardium, K1 (rate constant for transfer from arterial plasma to tissues) was used as a surrogate marker of perfusion to correct the binding potential for impaired radiotracer transfer from plasma to tissue (BPTC). Results: LW223 binding to TSPO was not susceptible to the rs6971 genetic polymorphism in human brain and heart samples. In rodents, 18F-LW223 displayed a specific uptake consistent with TSPO expression, a slow metabolism in blood (69% of parent at 120 min), a high plasma free fraction of 38.5%, and a suitable dosimetry profile (effective dose of 20.5-24.5 μSv/MBq). 18F-LW223 BPTC was significantly higher in the MI cohort within the infarct territory of the anterior wall relative to the anterior wall of naïve animals (32.7 ± 5.0 vs. 10.0 ± 2.4 cm3/mL/min, P ≤ 0.001). Ex vivo immunofluorescent staining for TSPO and CD68 (macrophage marker) resulted in the same pattern seen with in vivo BPTC analysis. Conclusion:18F-LW223 is not susceptible to the rs6971 genetic polymorphism in in vitro assays, has favorable in vivo characteristics, and is able to accurately map macrophage-driven inflammation after MI.
引用
- MacAskill MG, Stadulyte A, Williams L, et al. Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with 18F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism. J Nucl Med. 2020. PMID: 32859708. doi:10.2967/jnumed.120.243600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。